Journal article icon

Journal article

Redirecting adenoviruses to tumour cells using therapeutic antibodies: generation of a versatile human bispecific adaptor

Abstract:

Effective use of adenovirus-5 (Ad5) in cancer therapy is heavily dependent on the degree to which the virus's natural tropism can be subverted to one that favours tumour cells. This is normally achieved through either engineering of the viral fiber knob or the use of bispecific adaptors that display both adenovirus and tumour antigen receptors. One of the main limitations of these strategies is the need to tailor each engineering event to any given tumour antigen. Here, we explore bispecific ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.molimm.2015.08.014

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Biochemistry
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Biochemistry
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Biochemistry
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Biochemistry
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Biochemistry
Role:
Author
Expand authors...
Oxford Glycobiology Endowment More from this funder
More from this funder
Funding agency for:
Crispin, M
Department of Biochemistry, University of Oxford More from this funder
Expand funders...
Publisher:
Elsevier Publisher's website
Journal:
Molecular immunology Journal website
Volume:
68
Issue:
2 Pt A
Pages:
234-243
Publication date:
2015-12-01
Acceptance date:
2015-08-27
DOI:
EISSN:
1872-9142
ISSN:
0161-5890
Source identifiers:
568292
Language:
English
Keywords:
Pubs id:
pubs:568292
UUID:
uuid:4955ae90-2806-4ba4-90e5-40075d42b186
Local pid:
pubs:568292
Deposit date:
2016-02-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP